Concepts (215)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sepsis | 6 | 2023 | 274 | 0.930 |
Why?
|
| Invasive Pulmonary Aspergillosis | 1 | 2021 | 5 | 0.740 |
Why?
|
| Toll-Like Receptor 4 | 3 | 2013 | 339 | 0.710 |
Why?
|
| Hypoxia | 3 | 2024 | 112 | 0.560 |
Why?
|
| Respiratory Insufficiency | 4 | 2024 | 148 | 0.520 |
Why?
|
| Sugar Phosphates | 2 | 2013 | 3 | 0.480 |
Why?
|
| Disaccharides | 2 | 2013 | 10 | 0.480 |
Why?
|
| Intensive Care Units | 6 | 2021 | 423 | 0.460 |
Why?
|
| Hospital Mortality | 4 | 2021 | 842 | 0.410 |
Why?
|
| Cannula | 2 | 2024 | 25 | 0.400 |
Why?
|
| Respiration, Artificial | 6 | 2021 | 292 | 0.380 |
Why?
|
| Noninvasive Ventilation | 2 | 2024 | 70 | 0.370 |
Why?
|
| Lipid A | 1 | 2010 | 66 | 0.330 |
Why?
|
| Shock, Septic | 2 | 2023 | 86 | 0.320 |
Why?
|
| Integrins | 4 | 1997 | 106 | 0.310 |
Why?
|
| Double-Blind Method | 8 | 2024 | 715 | 0.300 |
Why?
|
| Bacterial Infections | 1 | 2010 | 140 | 0.300 |
Why?
|
| Lipopolysaccharides | 1 | 2011 | 627 | 0.290 |
Why?
|
| Mucoproteins | 2 | 1997 | 3 | 0.260 |
Why?
|
| Receptors, Lymphocyte Homing | 2 | 1997 | 15 | 0.260 |
Why?
|
| Immunoglobulins | 2 | 1997 | 76 | 0.250 |
Why?
|
| Critical Care | 4 | 2017 | 397 | 0.240 |
Why?
|
| Oxazines | 1 | 2024 | 13 | 0.230 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2004 | 35 | 0.230 |
Why?
|
| Morpholines | 1 | 2024 | 86 | 0.230 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2004 | 31 | 0.230 |
Why?
|
| Pyridines | 1 | 2024 | 98 | 0.220 |
Why?
|
| Guideline Adherence | 2 | 2021 | 292 | 0.220 |
Why?
|
| Propensity Score | 1 | 2024 | 144 | 0.210 |
Why?
|
| Clinical Trials as Topic | 3 | 2019 | 440 | 0.210 |
Why?
|
| Adult | 17 | 2024 | 15683 | 0.210 |
Why?
|
| Humans | 29 | 2024 | 59389 | 0.200 |
Why?
|
| Aged | 14 | 2024 | 13406 | 0.190 |
Why?
|
| Ventilator-Induced Lung Injury | 1 | 2021 | 11 | 0.180 |
Why?
|
| Male | 18 | 2024 | 27747 | 0.180 |
Why?
|
| Middle Aged | 15 | 2024 | 16314 | 0.180 |
Why?
|
| Female | 19 | 2024 | 30724 | 0.180 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 19 | 0.180 |
Why?
|
| Blood Gas Analysis | 2 | 2017 | 34 | 0.180 |
Why?
|
| Tidal Volume | 2 | 2019 | 37 | 0.170 |
Why?
|
| Patient Safety | 1 | 2020 | 237 | 0.150 |
Why?
|
| Acute Chest Syndrome | 1 | 2017 | 4 | 0.150 |
Why?
|
| Treatment Outcome | 6 | 2024 | 5281 | 0.140 |
Why?
|
| Blood Substitutes | 1 | 2017 | 5 | 0.140 |
Why?
|
| Integrin beta Chains | 1 | 1997 | 2 | 0.140 |
Why?
|
| Multiple Organ Failure | 1 | 2017 | 43 | 0.140 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2017 | 42 | 0.140 |
Why?
|
| Protein C | 2 | 2008 | 29 | 0.140 |
Why?
|
| Hemoglobins | 1 | 2017 | 133 | 0.130 |
Why?
|
| Thiamine Deficiency | 1 | 2016 | 6 | 0.130 |
Why?
|
| Thiamine | 1 | 2016 | 19 | 0.130 |
Why?
|
| Protein Structure, Tertiary | 1 | 1997 | 656 | 0.120 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 692 | 0.120 |
Why?
|
| Lactic Acid | 1 | 2016 | 71 | 0.120 |
Why?
|
| Cohort Studies | 3 | 2024 | 2375 | 0.120 |
Why?
|
| APACHE | 3 | 2010 | 46 | 0.120 |
Why?
|
| Shock | 1 | 2015 | 31 | 0.120 |
Why?
|
| Fluid Therapy | 1 | 2015 | 47 | 0.120 |
Why?
|
| Emergency Service, Hospital | 2 | 2024 | 1022 | 0.110 |
Why?
|
| Lymphocytes | 1 | 1994 | 190 | 0.110 |
Why?
|
| Infusions, Intravenous | 2 | 2010 | 163 | 0.100 |
Why?
|
| Severity of Illness Index | 4 | 2021 | 1479 | 0.100 |
Why?
|
| Prospective Studies | 3 | 2019 | 3067 | 0.090 |
Why?
|
| United States | 5 | 2021 | 7426 | 0.090 |
Why?
|
| Gram-Positive Bacteria | 1 | 2011 | 36 | 0.090 |
Why?
|
| Gram-Negative Bacteria | 1 | 2011 | 54 | 0.090 |
Why?
|
| Phospholipids | 1 | 2011 | 78 | 0.090 |
Why?
|
| Maximum Tolerated Dose | 1 | 2010 | 38 | 0.080 |
Why?
|
| Acute Disease | 2 | 2024 | 658 | 0.080 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 2338 | 0.080 |
Why?
|
| Renal Dialysis | 1 | 2011 | 189 | 0.080 |
Why?
|
| Antibodies, Neutralizing | 1 | 2011 | 178 | 0.080 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 284 | 0.080 |
Why?
|
| Choriocarcinoma | 1 | 2008 | 3 | 0.080 |
Why?
|
| Incidence | 2 | 2019 | 1238 | 0.080 |
Why?
|
| Drug Therapy, Computer-Assisted | 1 | 2008 | 10 | 0.080 |
Why?
|
| Survival Analysis | 1 | 2010 | 554 | 0.070 |
Why?
|
| Critical Illness | 2 | 2010 | 325 | 0.070 |
Why?
|
| Uterine Neoplasms | 1 | 2008 | 29 | 0.070 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2008 | 68 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 805 | 0.070 |
Why?
|
| Cell Adhesion Molecules | 3 | 1997 | 85 | 0.070 |
Why?
|
| Blood Glucose | 1 | 2008 | 461 | 0.060 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2005 | 41 | 0.060 |
Why?
|
| Treatment Failure | 2 | 2020 | 185 | 0.060 |
Why?
|
| Pyridazines | 1 | 2024 | 8 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2024 | 6071 | 0.060 |
Why?
|
| Insulin | 1 | 2008 | 673 | 0.060 |
Why?
|
| Anticoagulants | 1 | 2008 | 480 | 0.060 |
Why?
|
| Pyrimidines | 1 | 2024 | 131 | 0.060 |
Why?
|
| Polymyxin B | 1 | 2023 | 7 | 0.060 |
Why?
|
| Adaptive Clinical Trials as Topic | 1 | 2023 | 5 | 0.060 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2005 | 202 | 0.050 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2024 | 57 | 0.050 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2024 | 170 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2023 | 110 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2017 | 914 | 0.050 |
Why?
|
| Pulmonary Circulation | 1 | 2003 | 27 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2010 | 1925 | 0.050 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2023 | 73 | 0.050 |
Why?
|
| Immunosuppressive Agents | 1 | 2004 | 365 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 3 | 1997 | 450 | 0.050 |
Why?
|
| Hemodynamics | 1 | 2003 | 230 | 0.050 |
Why?
|
| Neuromuscular Blockade | 1 | 2021 | 8 | 0.050 |
Why?
|
| Early Medical Intervention | 1 | 2021 | 17 | 0.050 |
Why?
|
| Prone Position | 1 | 2021 | 27 | 0.050 |
Why?
|
| HIV Infections | 1 | 2008 | 913 | 0.050 |
Why?
|
| Positive-Pressure Respiration | 1 | 2021 | 46 | 0.050 |
Why?
|
| Vasodilator Agents | 1 | 2021 | 63 | 0.050 |
Why?
|
| Leukemia, Erythroblastic, Acute | 2 | 1997 | 6 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2011 | 2903 | 0.040 |
Why?
|
| Patient Positioning | 1 | 2021 | 44 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2023 | 217 | 0.040 |
Why?
|
| Heart | 1 | 2003 | 274 | 0.040 |
Why?
|
| Research Design | 1 | 2023 | 555 | 0.040 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2021 | 52 | 0.040 |
Why?
|
| Cell Adhesion | 3 | 1997 | 206 | 0.040 |
Why?
|
| Prognosis | 1 | 2004 | 1597 | 0.040 |
Why?
|
| HLA-DR Antigens | 1 | 2019 | 27 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2021 | 180 | 0.040 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2019 | 56 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 2 | 1997 | 490 | 0.040 |
Why?
|
| Transfection | 2 | 1997 | 675 | 0.040 |
Why?
|
| Intubation, Intratracheal | 1 | 2020 | 194 | 0.040 |
Why?
|
| Aged, 80 and over | 3 | 2016 | 5119 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2019 | 103 | 0.040 |
Why?
|
| Methemoglobinemia | 1 | 2017 | 3 | 0.040 |
Why?
|
| Microvilli | 1 | 1997 | 4 | 0.040 |
Why?
|
| Drug Evaluation | 1 | 2017 | 19 | 0.040 |
Why?
|
| Lung | 1 | 2003 | 920 | 0.040 |
Why?
|
| Jehovah's Witnesses | 1 | 2017 | 17 | 0.040 |
Why?
|
| Placebos | 1 | 2017 | 68 | 0.040 |
Why?
|
| Treatment Refusal | 1 | 2017 | 54 | 0.040 |
Why?
|
| Epitope Mapping | 1 | 1997 | 46 | 0.040 |
Why?
|
| North America | 1 | 2017 | 105 | 0.040 |
Why?
|
| Pregnancy | 1 | 2004 | 2213 | 0.040 |
Why?
|
| Hospitalization | 1 | 2024 | 1290 | 0.040 |
Why?
|
| Cations | 1 | 1997 | 63 | 0.030 |
Why?
|
| Oximetry | 1 | 2017 | 47 | 0.030 |
Why?
|
| Leukocytes | 1 | 1997 | 97 | 0.030 |
Why?
|
| Serine | 1 | 1997 | 83 | 0.030 |
Why?
|
| Erythrocyte Transfusion | 1 | 2017 | 72 | 0.030 |
Why?
|
| Cattle | 1 | 2017 | 304 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2021 | 513 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2019 | 526 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 705 | 0.030 |
Why?
|
| Survival Rate | 1 | 2019 | 801 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 2017 | 191 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 1997 | 365 | 0.030 |
Why?
|
| Cross Infection | 1 | 2017 | 149 | 0.030 |
Why?
|
| Ligands | 1 | 1997 | 411 | 0.030 |
Why?
|
| Young Adult | 2 | 2017 | 4272 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 2 | 1997 | 836 | 0.030 |
Why?
|
| Central Venous Pressure | 1 | 2015 | 12 | 0.030 |
Why?
|
| Water-Electrolyte Balance | 1 | 2015 | 17 | 0.030 |
Why?
|
| Furosemide | 1 | 2015 | 19 | 0.030 |
Why?
|
| Animals | 4 | 2017 | 19650 | 0.030 |
Why?
|
| Diuretics | 1 | 2015 | 59 | 0.030 |
Why?
|
| Risk Factors | 1 | 2004 | 4986 | 0.030 |
Why?
|
| Pneumonia | 1 | 2017 | 281 | 0.030 |
Why?
|
| Random Allocation | 1 | 2015 | 192 | 0.030 |
Why?
|
| Manganese | 1 | 1994 | 24 | 0.030 |
Why?
|
| Leukocyte Common Antigens | 1 | 1994 | 58 | 0.030 |
Why?
|
| Integrin beta1 | 1 | 1994 | 28 | 0.030 |
Why?
|
| Polymers | 1 | 2017 | 316 | 0.030 |
Why?
|
| Biomarkers | 1 | 2019 | 1307 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2015 | 136 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 1997 | 1951 | 0.030 |
Why?
|
| Cell Line | 2 | 1997 | 1983 | 0.030 |
Why?
|
| Rats | 1 | 1997 | 1910 | 0.030 |
Why?
|
| Organ Dysfunction Scores | 1 | 2013 | 19 | 0.030 |
Why?
|
| Protein Binding | 1 | 1997 | 1555 | 0.030 |
Why?
|
| Mice | 2 | 1997 | 10294 | 0.020 |
Why?
|
| Hypertension | 1 | 2017 | 570 | 0.020 |
Why?
|
| Intestines | 1 | 1993 | 158 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 396 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1993 | 244 | 0.020 |
Why?
|
| Immunologic Memory | 1 | 1993 | 283 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 1993 | 623 | 0.020 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 1 | 2008 | 3 | 0.020 |
Why?
|
| Respiratory Dead Space | 1 | 2008 | 2 | 0.020 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2008 | 15 | 0.020 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2008 | 60 | 0.020 |
Why?
|
| Viral Load | 1 | 2008 | 220 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2008 | 309 | 0.020 |
Why?
|
| Point-of-Care Systems | 1 | 2008 | 122 | 0.020 |
Why?
|
| Recurrence | 1 | 2008 | 602 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2008 | 180 | 0.020 |
Why?
|
| Drug Costs | 1 | 2005 | 54 | 0.020 |
Why?
|
| Software | 1 | 2008 | 366 | 0.010 |
Why?
|
| Muscles | 1 | 1984 | 173 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2008 | 1559 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2005 | 689 | 0.010 |
Why?
|
| Vascular Capacitance | 1 | 2003 | 2 | 0.010 |
Why?
|
| Cardiac Volume | 1 | 2003 | 7 | 0.010 |
Why?
|
| Ventricular Function | 1 | 2003 | 22 | 0.010 |
Why?
|
| Patient Selection | 1 | 2005 | 465 | 0.010 |
Why?
|
| Ventricular Pressure | 1 | 2003 | 30 | 0.010 |
Why?
|
| Vascular Resistance | 1 | 2003 | 48 | 0.010 |
Why?
|
| HIV-1 | 1 | 2008 | 692 | 0.010 |
Why?
|
| Diastole | 1 | 2003 | 89 | 0.010 |
Why?
|
| Adolescent | 1 | 2013 | 5838 | 0.010 |
Why?
|
| Microscopy, Immunoelectron | 1 | 1997 | 32 | 0.010 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 1997 | 14 | 0.010 |
Why?
|
| Macrophage-1 Antigen | 1 | 1997 | 31 | 0.010 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 1997 | 62 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1997 | 248 | 0.010 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 1993 | 15 | 0.010 |
Why?
|
| Fibronectins | 1 | 1993 | 43 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1993 | 2092 | 0.000 |
Why?
|
| Rhodamines | 1 | 1984 | 20 | 0.000 |
Why?
|
| Glycerol | 1 | 1984 | 31 | 0.000 |
Why?
|
| Muscle Relaxation | 1 | 1984 | 23 | 0.000 |
Why?
|
| Rabbits | 1 | 1984 | 322 | 0.000 |
Why?
|
| Models, Biological | 1 | 1984 | 1143 | 0.000 |
Why?
|